The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia

Wu, Yu; Ding, Yu An; Cao, Qiang; Qian, Subo; Wang, C; Duan, Huangqi; Gu, Jian; Shen, Haibo

doi:10.1007/s00345-020-03084-4

Cited by 9 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolic syndrome and its components of obesity, hyperinsulinemia, T2DM, dyslipidemia, and hypertension are significantly associated with BPH [ 89 90 91 92 93 ]. Therefore, metformin may not only reduce the risk of BPH via a direct effect on the prostate tissue, it may also act through indirect effects by correcting the metabolic dysregulations in the various components of metabolic syndrome.…”

Section: Prostate-related Healthmentioning

confidence: 99%

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Tseng

2022

World J Mens Health

View full text Add to dashboard Cite

Metformin is the first-line oral antidiabetic drug that shows multiple pleiotropic effects of anti-inflamation, anti-cancer, anti-aging, anti-microbia, anti-atherosclerosis, and immune modulation. Metformin's effects on men's related health are reviewed here, focusing on reproductive health under subtitles of erectile dysfunction (ED), steroidogenesis and spermatogenesis; and on prostate-related health under subtitles of prostate specific antigen (PSA), prostatitis, benign prostate hyperplasia (BPH), and prostate cancer (PCa). Updated literature suggests a potential role of metformin on arteriogenic ED but controversial and contradictory effects (either protective or harmful) on testicular functions of testosterone synthesis and spermatogenesis. With regards to prostate-related health, metformin use may be associated with lower levels of PSA in humans, but its clinical implications require more research. Although there is a lack of research on metform's effect on prostatitis, it may have potential benefits through its anti-microbial and anti-inflammatory properties. Metformin may reduce the risk of BPH by inhibiting the insulin-like growth factor 1 pathway and some but not all studies suggest a protective role of metformin on the risk of PCa. Many clinical trials are being conducted to investigate the use of metformin as an adjuvant therapy for PCa but results currently available are not conclusive. While some trials suggest a benefit in reducing the metastasis and recurrence of PCa, others do not show any benefit. More research works are warranted to illuminate the potential usefulness of metformin in the promotion of men's health.

show abstract

Section: Prostate-related Healthmentioning

confidence: 99%

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Tseng

2022

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…This finding was consistent with previous studies which found that there was an association between hyperglycemia and prostate size and that abnormal glucose was correlated with prostate enlargement. In patients younger than 70 years, compared with the normal glucose group, the adjusted odds ratio for prostate volume enlargement in the prediabetic group and the diabetic group was 2.27 (95% CI 1.29 -4.00) and 4.74 (95% CI 2.18 -10.30) respectively (6). Prostate volume was found to be higher in patients with HbA1c levels ≥6.5% (45.69±3.97 vs. 36.64±3.30) (7) While the precise mechanism was still unclear, there are several proposed mechanisms on how blood glucose could impact prostate enlargement.…”

Section: Discussionmentioning

confidence: 93%

“…Evidence showed that hyperglycemia is considered to take part in the development of prostate enlargement (6). Although, the association between the two is still unclear.…”

Section: Introductionmentioning

confidence: 99%

Correlation of blood glucose and prostatic-related parameters in patients with prostate enlargement

YATİNDRA¹,

PRABANDARİ²,

TİRTAYASA³

et al. 2023

J Exp Clin Med

View full text Add to dashboard Cite

Enlarged prostate, either in benign prostatic hyperplasia or prostate cancer is the predominant urological disease affecting older men. Metabolic syndrome including high blood glucose was considered to take part in the development of prostate enlargement, although their association is still unclear. This study aims to investigate the correlation between blood glucose with prostatic-related parameters. A cross-sectional study was conducted involving 91 men with prostate enlargement from Urology Polyclinic, Tabanan Hospital, Bali Province, Indonesia. Prostatic-related parameters collected include patient’s international prostate symptoms score using the questionnaire, prostate-specific antigen and random blood glucose analysis from serum blood sample, and prostate volume determined with transabdominal ultrasonography. Patient’s mean age was 65.4 ± 10 years, mean prostate volume 52.7 ± 26 ml, mean prostate-specific antigen (PSA) 9.2 ± 17 ng/ml, mean international prostatic symptoms score (IPSS) 14.31 ± 7.1, mean random blood glucose 121.1 ± 40.5 mg/dl. This study found weak positive correlation between random blood glucose and prostate volume (r=0.269; p=0.01). PSA and prostate volume showed moderate positive correlation (r=0.365; p<0.001). No correlation between random blood glucose with PSA or IPSS was found in this study. This study found random blood glucose has positive correlation with prostate volume. We recommend enhancing blood glucose control to prevent the progress of prostate enlargement.

show abstract

“…Clinical guidelines state that choosing the appropriate surgical procedure according to the prostate size can reduce complications and is vital to improving patients’ quality of life ( 21 – 23 ). Although hyperglycemia has been reported to increase prostate volume ( 24 , 25 ), and lymphocytes, free/total prostate-specific antigen ( 26 ), neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio have been associated with BPH ( 27 ), these did not analyze in detail or separately the relationship between prostate volume and hematological parameters. An analysis of platelet and monocyte-to-lymphocyte ratio and diabetes mellitus with benign prostatic enlargement is not reported in related article.…”

Section: Introductionmentioning

confidence: 99%

Analysis of platelet and monocyte-to-lymphocyte ratio and diabetes mellitus with benign prostatic enlargement

Chen

2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThe etiology of benign prostatic hyperplasia (BPH) is still elusive. The aim of this study was to provide preventive and prognostic parameters associated with diabetes mellitus with benign prostatic enlargement (BPE).MethodsDiabetic patients were collected retrospectively from February 2021 to December 2022, including monocyte-to-lymphocyte ratio (MLR). Diabetic patients were divided into two groups by whether the prostate volume was greater than or equal to 30 ml, which were diabetes mellitus without BPE (DM) and diabetes mellitus with BPE (DM+BPE). The baseline characteristics were compared, the risk and protective factors associated with DM+BPE were determined using univariate and multivariate logistic regression, and the parameters associated with prostate volume were determined using correlation analysis.ResultsOf the 671 patients collected, age and prostate volume were significantly higher in the DM+BPE than in the DM; MLR was higher in the DM+BPE than in the DM; and platelet was significantly lower in the DM+BPE than in the DM. Univariate logistic regression showed that age was a risk factor, while protective factors for DM+BPE were lymphocytes and platelet. Multifactorial logistic regression showed that age was a risk factor, while platelet was the protective factor for DM+BPE. In the total overall (n=671), prostate volume was positively correlated with age. Prostate volume was negatively correlated with lymphocytes and platelet. In DM+BPE (n=142), prostate volume was positively correlated with age and MLR.ConclusionPlatelet was a protective factor for DM+BPE and was negatively correlated with prostate volume, whereas MLR was positively correlated with prostate volume in DM+BPE.

show abstract

The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia

Cited by 9 publications

References 31 publications

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Correlation of blood glucose and prostatic-related parameters in patients with prostate enlargement

Analysis of platelet and monocyte-to-lymphocyte ratio and diabetes mellitus with benign prostatic enlargement

Contact Info

Product

Resources

About